Initial Studies Show Harbor BioSciences, Inc. (HRBR)' Triolex(R) for Parkinson's Disease Crosses the Blood-Brain Barrier in Mice
2/22/2011 9:43:35 AM
SAN DIEGO, Feb. 22, 2011 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (OTCBB:HRBR), which is investigating the use the company's proprietary compound Triolex® as a treatment for Parkinson's disease (PD) with funding from The Michael J. Fox Foundation (MJFF), announced positive results in initial preclinical studies. These studies in orally treated mice demonstrate that Triolex crosses the blood-brain barrier in significant quantities.
comments powered by